Lexicon Pharmaceuticals (LXRX) Net Cash Flow Growth (3y) (2013 - 2026)
Lexicon Pharmaceuticals (LXRX) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 32.17% |
| 10 | Lexicon Pharmaceuticals | 922.55 Mn | 751.90 Mn | 20.99 Mn | 29.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.76% |
| Dec 31, 2025 | -36.75% |
| Sep 30, 2025 | 134.01% |
| Jun 30, 2025 | 30.97% |
| Mar 31, 2025 | 6.06% |
| Dec 31, 2024 | 46.50% |
| Sep 30, 2024 | -35.32% |
| Jun 30, 2024 | -98.66% |
| Mar 31, 2024 | 66.16% |
| Dec 31, 2023 | -73.68% |
| Sep 30, 2023 | -32.75% |
| Jun 30, 2023 | 34.49% |
| Mar 31, 2023 | -44.93% |
| Dec 31, 2022 | 30.16% |
| Sep 30, 2022 | -26.34% |
| Jun 30, 2022 | -3.17% |
| Mar 31, 2022 | 49.17% |
| Dec 31, 2021 | -42.46% |
| Sep 30, 2021 | -59.61% |
| Jun 30, 2021 | -13.03% |